Primary & Urgent Care South Internal Medicine Medicare: Medicare Enrolled Practice Location: 143 White Oak Trl, Warrior, AL 35180 Phone: 205-647-1819 |
Warrior Medical Associates, Pc Internal Medicine Medicare: Medicare Enrolled Practice Location: 100 Dana Road, Warrior, AL 35180 Phone: 205-647-6333 Fax: 205-647-8666 |
Warrior Family Medicine Clinic/Center - Multi-Specialty Medicare: Not Enrolled in Medicare Practice Location: 151 5th St E, Warrior, AL 35180 Phone: 205-647-0526 Fax: 205-647-0527 |
Rural Primary Care South, Inc. Clinic/Center - Rural Health Medicare: Medicare Enrolled Practice Location: 143 White Oak Trl, Suite 2, Warrior, AL 35180 Phone: 205-647-1819 |
News Archive
Bionovo, Inc. announced today the publication of their results from its phase 1B clinical trial of Bezielle (BZL101) for metastatic breast cancer. The results of the study are available online in Breast Cancer Research and Treatment and demonstrate that Bezielle continues to be safe and well tolerated with clinical evidence of anticancer activity in a heavily pretreated population of women diagnosed with metastatic breast cancer.
Efforts to support older people during extreme heat should focus on those who lack independence or have pre-existing health issues, according to an expert from the University of Warwick.
In a study examining the relationship between racial/ethnic neighborhood concentration and self-reported health, researchers at Columbia University's Mailman School of Public Health found that individuals living in neighborhoods with a high concentration of Blacks were twice as likely to report poor health when compared to their counterparts living in neighborhoods with a lower concentration of Blacks.
The Department of Health and Human Services today announced a proposed rule that, according to an agency press release, lays out "how nonprofit religious organizations, such as nonprofit religious hospitals or institutions of higher education, that object to contraception on religious grounds can receive an accommodation that provides their enrollees separate contraceptive coverage, and with no co-pays, but at no cost to the religious organization."
Warner Chilcott plc today announced that it has agreed to terminate its existing co-promotion agreement with Novartis and signed a definitive agreement to purchase the U.S. rights to Enablex® from Novartis for $400 million in cash. Enablex (darifenacin) is a product indicated to treat adults with symptoms of overactive bladder, which had U.S. sales of approximately $190 million for the year ended December 31, 2009.
› Verified 6 days ago